Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Clinical Trial ID: NCT03827876

Description

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.


Criteria

Inclusion Criteria: - Male or female adult ≥ 18 years of age; - Diagnosis of chronic plaque-type - Patient with 2-10% BSA - Physician Global Assessment of 2 or greater - Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks Exclusion Criteria: - ˂2 or >10% BSA - PGA <2 - Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks

  • Start Date

    2019-01-16

  • Last Updated

    2019-01-31

  • Sponsor

    LEO Pharma

  • Condition Name

    Psoriasis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.